Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04344600 · ClinicalTrials.gov registry record · Phase 2
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04344600: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT04344600 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04344600, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a phase 2b prospective, randomized, single-blind, controlled trial of a single subcutaneous injection of peginterferon lambda-1a versus placebo for prevention of SARS-CoV-2 infection in non-hospitalized participants at high risk for infection due to household exposure to an individual with coronavirus disease (COVID-19). The study will also evaluate the regimens participants with asymptomatic SARS-CoV-2 infection detected at study entry. All participants will be followed for up to 12 weeks.
Interventions
- OTHER Saline
- DRUG Peginterferon lambda alfa-1a subcutaneous injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-06-29 |
| Est. Completion | 2021-09-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04344600
The ClinicalTrials.gov registry entry for NCT04344600 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT04344600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04344600 about?
NCT04344600 is a clinical study titled "Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection". This is a phase 2b prospective, randomized, single-blind, controlled trial of a single subcutaneous injection of peginterferon lambda-1a versus placebo for prevention of SARS-CoV-2 infection in non-hospitalized participants at high risk for infection due to household exposure to an individual with c...
What is the current status of trial NCT04344600?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2020-06-29. Estimated completion is 2021-09-24.
What interventions are being tested in trial NCT04344600?
The interventions under investigation include: Saline (OTHER), Peginterferon lambda alfa-1a subcutaneous injection (DRUG).
Who is sponsoring clinical trial NCT04344600?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.